ALMS_OUT_1 [2025-03-25 08:39:05 -0400] 2047 Bytes | 585 tokens | Cum: 585 tkns (7.31% of 8k)
==========================================================================

Alright, let’s light it up, because it's 8:39:03 AM on Tue Mar 25, 2025 -0400, and I'm charging into Alumis (ALMS), popping from 3.775 to 5. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for Alumis:

C1 - Today 02:30AM - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
C2 - Mar-21-25 07:08AM - Why Alumis Inc. (ALMS) Went Down On Thursday?
C3 - Mar-19-25 04:05PM - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
C4 - Mar-10-25 08:00AM - Alumis to Present at Leerink's 2025 Global Healthcare Conference
C5 - Mar-08-25 09:00AM - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
C6 - Mar-04-25 09:01AM - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
C7 - Mar-04-25 09:01AM 09:01AM - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
C8 - Mar-04-25 09:01AM 09:00AM - ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Alumis (ALMS)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ALMS_OUT_3 [2025-03-25 08:39:08 -0400] 1039 Bytes | 316 tokens | Cum: 903 tkns (11.29% of 8k)
==========================================================================

Showing C5 (chunk 1 of 11): C5:
**Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis**
Date: Mar-08-25 09:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/08/3039351/0/en/Late-Breaking-ESK-001-Phase-2-OLE-Data-Presented-at-2025-AAD-Annual-Meeting-Demonstrate-Robust-Clinical-Responses-Over-52-Weeks-in-Psoriasis.html

March 08, 2025 09:00 ET| Source:Alumis Inc.Alumis Inc.

SOUTH SAN FRANCISCO, Calif., March 08, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 52-week data from the open-label extension (OLE) of its Phase 2 STRIDE clinical trial evaluating ESK-001

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_5 [2025-03-25 08:39:09 -0400] 1029 Bytes | 293 tokens | Cum: 1198 tkns (14.97% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-25T12:10:17Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - BioSig Technologies (NASDAQ:BSGM), Al...
A2 - 2025-03-25T07:38:24Z - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermat...
A3 - 2025-03-25T06:45:00Z - Alumis And Kaken Pharma Partner To Advance ESK-001 TYK2 Inhibitor For Dermatology In Japan...
A4 - 2025-03-25T06:40:04Z - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermat...
A5 - 2025-03-25T06:50:06Z - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermat...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALMS_OUT_7 [2025-03-25 08:39:11 -0400] 1038 Bytes | 319 tokens | Cum: 1519 tkns (18.99% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Tuesday's Pre-Market Session - BioSig Technologies (NASDAQ:BSGM), Alumis (NASDAQ:ALMS)**Date: 2025-03-25Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44471681/12-health-care-stocks-moving-in-tuesdays-pre-market-sessionGainers Tenon Medical TNON stock increased by 367.2% to $4.57 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.3 million. The company's, Q4 earnings came out 3 days ago. Predictive Oncology POAI shares rose 104.48% to $2.28. The company's market cap stands at $16.4 million. Palatin Techs PTN shares increased by 17.04% to $0.88. The company's market cap stands at $22.9 million. Alumis ALMS stock increased by 16.29% to $4.39. The company's market cap stands at $238.8 million. Know Labs KNW stock increased by 14.28% to $

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_9 [2025-03-25 08:39:12 -0400] 1038 Bytes | 305 tokens | Cum: 1826 tkns (22.82% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): 1.2. The company's market cap stands at $3.3 million. BioSig Technologies BSGM shares increased by 10.34% to $0.54. The company's market cap stands at $12.9 million. Losers Mural Oncology MURA stock declined by 49.6% to $1.93 during Tuesday's pre-market session. The market value of their outstanding shares is at $33.2 million. Orchestra BioMed Hldgs OBIO shares declined by 17.95% to $3.75. The market value of their outstanding shares is at $141.8 million. Cyclo Therapeutics CYTH stock decreased by 12.77% to $0.62. The company's market cap stands at $20.2 million. GlucoTrack GCTK stock declined by 10.52% to $0.24. The market value of their outstanding shares is at $3.1 million. Inspire Veterinary IVP shares decreased by 10.39% to $1.64. The market value of their outstanding shares is at $2.4 million. Capstone Holding CAPS stock declined by 9.75% to $2.5. The company's market cap stands at

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_11 [2025-03-25 08:39:18 -0400] 981 Bytes | 328 tokens | Cum: 2156 tkns (26.95% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): $3.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMSAlumis Inc$4.3013.9%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum-Growth-Quality-Value-Price TrendShortMediumLongOverviewBSGMBioSig Technologies Inc$0.548811.1%CAPSCapstone Holding Corp$2.51-9.39%CYTHCyclo Therapeutics Inc$0.6497-8.58%GCTKGlucoTrack Inc$0.2517-6.78%IVPInspire Veterinary Partners Inc$1.840.55%KNWKnow Labs Inc$1.2216.2%MURAMural Oncology PLC$2.10-45.2%OBIOOrchestra BioMed Holdings Inc$3.75-17.9%POAIPredictive Oncology Inc$2.75145.5%PTNPalatin Technologies Inc$0.81007.58%TNONTenon Medical Inc$4.30339.6%Market News and Data brought to you by Benzinga APIs

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_13 [2025-03-25 08:39:20 -0400] 1096 Bytes | 341 tokens | Cum: 2591 tkns (32.39% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-19T20:05:00Z - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
B2 - 2025-03-13T17:52:00Z - Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGR
B3 - 2025-03-08T14:00:00Z - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
B4 - 2025-03-04T14:01:00Z - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
B5 - 2025-03-04T14:01:00Z - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
B6 - 2025-02-06T21:15:00Z - Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_15 [2025-03-25 08:39:25 -0400] 699 Bytes | 171 tokens | Cum: 2764 tkns (34.55% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/g44405196/alumis-reports-year-end-2024-financial-results-and-highlights-recent-achievementsAlumis reported strong 2024 results, with progress on its late-stage pipeline of oral TYK2 inhibitors for immune-mediated diseases. The company also announced a merger agreement with ACELYRIN to create a combined company with a differentiated portfolio and increased financial flexibility.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_17 [2025-03-25 08:39:26 -0400] 1102 Bytes | 287 tokens | Cum: 3118 tkns (38.98% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related note...

S2 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99....

S3 - 2025-03-04 8-K Item 7.01. Regulation FD Disclosure.

A joint press release issued by Alumis Inc. (the Company) and ACELYRIN, Inc. announcing that they have reaffirmed their commitment to merge in an all-stock transaction was issued on March 4, 2025 and is attached as Exhibit 99.1 to this Curre...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_19 [2025-03-25 08:39:28 -0400] 1038 Bytes | 195 tokens | Cum: 3315 tkns (41.44% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives and expectations for our business. Our actual results and the timing of selected events could differ materially from those described or implied by these forward-looking statements as a r

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_21 [2025-03-25 08:39:30 -0400] 1038 Bytes | 234 tokens | Cum: 3551 tkns (44.39% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): esult of several factors, including those set forth under Part I, Item 1A. Risk Factors in this Annual Report on Form 10-K. See also see the section titled Special Note Regarding Forward-Looking Statements.

Overview

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words allumerFrench for illuminateand immunisLatin for the immune system.

We are a clinical stage biopharmaceutical company with an initial focus on developing our two TYK2 inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a CNS penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, and is currently being eval

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_23 [2025-03-25 08:39:32 -0400] 1038 Bytes | 253 tokens | Cum: 3806 tkns (47.58% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): uated in an additional Phase 2 clinical trial in patients with SLE, for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we have initiated our Phase 3 ONWARD clinical program, which consists of two parallel Phase 3 clinical trials of ESK-001 in this indication and for which we expect to report topline results in the first quarter of 2026. These parallel Phase 3 clinical trials also include one LTE study, ONWARD3. In addition, the OLE of our Phase 2 clinical trial in PsO remains ongoing. TYK2 genetic mutations are associated with a strong protective effect in MS, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and reported initial results in

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_25 [2025-03-25 08:39:33 -0400] 1038 Bytes | 225 tokens | Cum: 4033 tkns (50.41% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): December 2024.

Alumis was incubated by Foresite Labs and incorporated on January 29, 2021, as a Delaware corporation under the name FL2021-001, Inc. FL2021-001, Inc.s name was changed to Esker Therapeutics, Inc. in March 2021, and to Alumis Inc. in January 2022.

Since our inception, we have devoted substantially all of our efforts to organizing our company, hiring personnel, business planning, acquiring and developing our product candidates, performing research and development, conducting preclinical studies and clinical trials, establishing and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these activities. We do not have any products approved for sale and have not generated any revenue from product sales. We expect to continue to incur significant and increasing expenses and increasing substantial losses for the

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_27 [2025-03-25 08:39:35 -0400] 1038 Bytes | 203 tokens | Cum: 4238 tkns (52.98% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): foreseeable future as we continue our development of and seek regulatory approvals for our product candidates and commercialize any approved products, seek to expand our product pipeline and invest in our organization. Our ability to achieve and sustain profitability will depend on our ability to successfully develop, obtain regulatory approval for and commercialize our product candidates. There can be no assurance that we will ever earn revenue or achieve profitability, or if achieved, that the revenue or profitability will be sustained on a continuing basis.

To date, we have primarily funded our operations with proceeds from sales of shares of our common stock and redeemable convertible preferred stock and the issuance of convertible promissory notes in private placements. In July 2024, we closed our IPO and the Concurrent Private Placement and received $233.3 million in net proceeds,

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_29 [2025-03-25 08:39:49 -0400] 5310 Bytes | 1538 tokens | Cum: 5778 tkns (72.22% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| Volume: 209,199 | SMA50: -33.18% | Market Cap: 205.39M | Option/Short: No / No | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| Avg Volume: 207.03K | SMA200: -60.41% | Shs Outstand: 47.22M | Short Float: 11.63% | Employees: 168 | EPS Surprise: -24.94% |
+---------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| Rel Volume: 1.03 | Perf Week: -12.82% | Shs Float: 25.25M | Short Ratio: 14.19 | Debt/Eq: 0.12 | P/E: - |
+---------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| RSI (14): 31.22 | Perf Month: -26.98% | Inst Own: 34.73% | Short Interest: 2.94M | Sales Y/Y TTM: - | Earnings: Mar 19 AMC |
+---------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| ATR (14): 0.50 | Perf Quarter: -55.22% | Insider Own: 53.59% | Beta: - | ROE: -198.66% | |
+---------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+
| SMA20: -16.71% | Index: RUT | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -101.72% | |
+---------------------+-----------------------+----------------------+-----------------------+----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: ALUMIS INC. (ALMS) by Babler Martin (President, CEO and Chairman) on 2025-02-18
- Stock Option (Right to Buy): 523000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Goldstein David M (Chief Scientific Officer) on 2025-02-18
- Stock Option (Right to Buy): 180000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Drappa Jorn (Chief Medical Officer) on 2025-02-18
- Stock Option (Right to Buy): 180000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Klein Sara (Chief Legal Officer) on 2025-02-18
- Stock Option (Right to Buy): 180000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Bradley Mark Christopher (Chief Development Officer) on 2025-02-18
- Stock Option (Right to Buy): 140000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Schroer John R. (Chief Financial Officer) on 2025-02-18
- Stock Option (Right to Buy): 140000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Richardson Derrick (SVP, People and Culture) on 2025-02-18
- Stock Option (Right to Buy): 50000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: Alumis Inc. Common Stock
Market Cap: 205387659.42499998
Shares Outstanding: 54407327
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -294233000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.775
Average Volume: 182589.9
30-Day High: 5.24
30-Day Low: 3.57

[Detailed Financials: TTM 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $123,499,000.0

[Detailed Financials: FY 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $123,499,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ALMS_OUT_31 [2025-03-25 08:39:51 -0400] 676 Bytes | 167 tokens | Cum: 6212 tkns (77.65% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ALMS_IN_33 [2025-03-25 08:39:52 -0400] 126 Bytes | 29 tokens | Cum: 6269 tkns (78.36% of 8k)
==========================================================================

====================================
[2025-03-25 05:39:52] # Analysis Completed
Elapsed Time: 49.26 seconds